Latest breakthroughs in cancer research, treatment, and prevention
497 articles
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
A Danish cohort of 49,894 adults shows first-time seizures carry a 76-fold elevated risk of neurological cancer and double the risk of non-neurological cancers within one year.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
A new agentic AI framework autonomously generates biological concepts from pathology images, identifying prognostic and predictive cancer biomarkers without manual feature engineering.
A novel cell-labeling tool reveals how ERα+ macrophages create immune-excluded niches in bone, blocking T cells from destroying cancer.
Specific mutational signatures accumulate linearly with age in normal tissues, offering a new window into why cancer risk rises exponentially as we get older.
A clinical trial in Nature Cancer shows an AI model meaningfully boosts diagnostic accuracy for lung nodules, a critical step in early cancer detection.
A 156-patient multimodal study reveals two distinct immune microenvironments in breast cancer brain metastases that predict survival and immunotherapy response.
A new AI model spots pancreatic cancer on standard CT scans nearly 16 months before radiologists can see it — with nearly 3x their sensitivity.
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
Zongertinib and sevabertinib earn FDA accelerated approvals for HER2-mutant NSCLC, expanding targeted therapy options for a historically hard-to-treat subset.
